Will Sun build on Zenotech toehold in biosimilars?
This article was originally published in Scrip
Executive Summary
Sun Pharma's indirect holding in Zenotech Laboratories, through its acquisition of Ranbaxy, gives it access to a clutch of biosimilar products, though unresolved, long-running disputes with Zenotech's founder have left the once promising biotech financially stretched.